Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OW2S
|
|||
| Former ID |
DNCL001707
|
|||
| Drug Name |
AMG 145
|
|||
| Indication | Hypercholesterolaemia [ICD-11: 5C80.0] | Phase 3 | [1] | |
| Company |
Amgen Thousand
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Target Info | Modulator | [2] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01854918) Open Label Study of Long Term Evaluation Against LDL-C Trial-2. U.S. National Institutes of Health. | |||
| REF 2 | PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015 Jan 24;385(9965):331-40. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.